Morningstar - adidas AG (ADDYY) Adidas on Track for Another Strong Growth Year Ahead; Shares Rich

Report

Morningstar

Jaime Katz

EUR 101.80 For Business Accounts Only

Adidas on Track for Another Strong Growth Year Ahead; Shares Rich

Narrow-moat Adidas closed on another strong year in 2016, with currency neutral revenue rising 18%, as merchandise has been spot on across major categories and regions. The firm benefited from strength in the Adidas brand (up 22%) but also sport performance, originals, and neo, which generated double-digit improvement. Core regions, including Western Europe, North America, and Greater China all experienced growth above 20%.
We plan to raise our $96 fair value estimate materially to account for ...

08/03/2017 13 EN

Underlying

adidas AG

See profile

Provider

Morningstar

Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.

Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.

We have operations in 27 countries.

See profile

Analysts

Jaime Katz

Other Reports on these Companies

Morningstar

Adidas Continues Its Robust Growth, but Where Does Further Margin Upside Come From?

There is no denying that Adidas continues to fire on all cylinders, as it posted first-quarter results showing strong sales and subsequent leverage of expenses that place the firm tracking moderately above our full-year estimates. Currency-neutral sales were up 10% (2% including foreign currency), on top of the 16% (19% including foreign exchange) posted last year, which aligns with our full-year 10% top-line estimate. However, these sales better leveraged the firmâ€™s expense base, resulting in m...

EUR 100.00

May 4, 2018 May 4, 2018 13 EN

Morningstar

Adidasâ€™ brand equity continues to resonate across the globe as consumers opt for its retro wear.

Narrow-moat Adidas posted fourth-quarter results that showed a continuation of strong sales and a subsequent leverage of expenses, as consumers opt for its on-trend athleisure wear. Currency-neutral sales were up 19% (12.4% including foreign exchange) for the quarter, on top of 12% growth last year, and gross margins increased 220 basis points to 51.7%, which placed full-year 2017 in line with our expectations. Amid continued competition, management expects this trajectory to continue, as eviden...

EUR 100.00

March 15, 2018 March 15, 2018 12 EN

Morningstar

Adidasâ€™ brand equity continues to resonates globally as consumers opt for its 'retrowear.'

Narrow-moat Adidas reported third-quarter results that continue to place the firm on track to meet our full-year assumptions that call for currency-neutral sales growth of 13%, gross margins that increase 140 basis points to 50%, and operating income margin around 9%. Despite results continuing to show strong growth and margin expansion in recent periods, we view the company as a beneficiary of short-term fashion trends and think that this pace of growth is unsustainable. Within this framework, ...

EUR 101.80

November 10, 2017 November 10, 2017 13 EN

Business as Usual for No-Moat Lonza; Specialty Ingredients Carve-Out on Track for 2020

Contract manufacturer Lonza reported solid half-year results, with over CHF 2.9 billion in total sales year to date, up about 6.4% from last year and boosted by foreign exchange tailwinds. Core EBITDA margin expanded 30 basis points from last year to about 27.8%, helped slightly by new accounting standards. Management indicated that it continues to expect mid- to high-single-digit sales growth in 2019. We are maintaining our fair value estimate of CHF 210 per share and our no-moat rating. The ph...

EUR 100.00

July 25, 2019 July 25, 2019 13 EN

Damien Conover

Damien Conover

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

We don't expect any major changes to our AstraZeneca fair value estimate following second-quarter results that largely fell in line with our expectations and slightly ahead of consensus expectations. Overall, the company is posting leading Big Pharma sales growth with total sales up 18% operationally year over year, led by impressive cancer drug sales growth of 57%. Astra's ability to continue to bring next generation drugs to the market that address unmet medical need (especially in oncology) s...

EUR 100.00

July 25, 2019 July 25, 2019 14 EN

Damien Conover

Damien Conover

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

EUR 100.00

July 25, 2019 July 25, 2019 14 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Adidas on Track for Another Strong Growth Year Ahead; Shares Rich

Adidas Continues Its Robust Growth, but Where Does Further Margin Upside Come From?

Adidasâ€™ brand equity continues to resonate across the globe as consumers opt for its retro wear.

Adidasâ€™ brand equity continues to resonates globally as consumers opt for its 'retrowear.'

Business as Usual for No-Moat Lonza; Specialty Ingredients Carve-Out on Track for 2020

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe